- Home
- EQX vs JAZZ Comparison
EQX vs JAZZ Comparison
Compare EQX & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQX | JAZZ |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 16.1B |
| IPO Year | 2018 | 2007 |
Fundamental Metrics
Financial Performance| Metric | EQX | JAZZ |
|---|---|---|
| Price | $12.21 | $241.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $17.00 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 10.3M | 895.8K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 7.17 |
| Revenue | N/A | ★ $1,618,693,000.00 |
| Revenue This Year | $102.84 | $6.22 |
| Revenue Next Year | $15.55 | $7.68 |
| P/E Ratio | $137.41 | ★ $33.44 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.49 | $125.79 |
| 52 Week High | $18.96 | $266.38 |
Technical Indicators
Market Signals| Indicator | EQX | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 45.12 |
| Support Level | $11.94 | $240.63 |
| Resistance Level | $15.14 | $242.66 |
| Average True Range (ATR) | 0.40 | 5.38 |
| MACD | -0.15 | -0.39 |
| Stochastic Oscillator | 40.65 | 34.07 |
Price Performance
Historical ComparisonAbout EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. The company operates gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the Canada, United States, Mexico, and others. The majority of its revenue is generated from Canada.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.